Rose bengal sodium is under clinical development by Provectus Biopharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rose bengal sodium’s likelihood of approval (LoA) and phase transition for Uveal Melanoma took place on 28 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rose bengal sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rose bengal sodium overview

PV-10 is under development for the treatment of neuroendocrine tumors, hepatocellular carcinoma, metastatic colorectal cancer, uveal melanoma, metastatic melanoma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer and pediatric solid tumor including  neuroblastoma, relapsed or refractory acute myelomonocytic leukemia (AML) and acute lymphocytic leukemia, testicular cancer, liver cancer,  psoriasis, atopic dermatitis, pediatric solid tumor including  Ewing sarcoma, rhabdosarcoma, osteosarcoma. The drug candidate is administered as an intralesional injection, oral and topical route. PV-10 is a formulation of rose bengal disodium, which is an iodinated fluorescein derivative. It was also under development for the treatment of basal cell carcinoma (basal cell epithelioma), squamous cell carcinoma, head and neck cancer, bladder cancer, breast cancer, prostate cancer and non-small cell lung cancer.

Provectus Biopharmaceuticals overview

Provectus Biopharmaceuticals (Provectus) is a developer of pharmaceuticals for oncology and dermatology indications compmay. The company offers pipeline products such as PV-10 for locally advanced cutaneous melanoma, PV-10 for metastatic liver cancer and PV-10 for neuroendocrine tumors [NET], pediatric solid tumors and other tumors. It also involve in developing a new class of drugs based on halogenated xanthenes such as Rose Bengal. Provectus also offers PH-10 for psoriasis and atopic dermatitis. The company conducts research on ongoing clinical trials for indications including breast cancers, melanoma, head and neck cancers, basal cell carcinoma and squamous cell carcinoma. Provectus is headquartered in Knoxville, Tennessee, the US.

Quick View Rose bengal sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Rose bengal sodium
Administration Pathway
  • Intralesional
  • Oral
  • Topical
Therapeutic Areas
  • Dermatology
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.